These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35757353)

  • 1. Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis.
    Dai L; Xu J; Jiang Y; Chen K
    Front Cardiovasc Med; 2022; 9():905607. PubMed ID: 35757353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.
    Wen M; Li Y; Qu X; Zhu Y; Tian L; Shen Z; Yang X; Shi X
    BMC Cardiovasc Disord; 2020 Oct; 20(1):430. PubMed ID: 33004000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Laine M; Toesca R; Berbis J; Frere C; Barnay P; Pansieri M; Peyre JP; Michelet P; Bessereau J; Camilleri E; Helaf O; Camaleonte M; Paganelli F; Dignat-George F; Bonello L
    Thromb Res; 2013 Jul; 132(1):e15-8. PubMed ID: 23726090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
    Galli M; Rollini F; Been L; Zenni MM; Angiolillo DJ; Franchi F
    J Thromb Thrombolysis; 2022 Oct; 54(3):461-469. PubMed ID: 36048358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
    Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
    Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention.
    Song K; Jin X; Kim MH; Li JX; Jin CD; Yuan SL; Song ZY; Jin EZ; Lee KM; Lim KH; Cho YR
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome.
    Laine M; Panagides V; Frère C; Cuisset T; Gouarne C; Jouve B; Lemesle G; Paganelli F; Alessi MC; Mancini J; Bonello L
    Thromb Haemost; 2021 Jul; 121(7):923-930. PubMed ID: 33260230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
    Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
    Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is platelet function testing at the acute phase under P2Y
    Bal Dit Sollier C; Berge N; Hamadouche S; Brumpt C; Stepanian A; Henry P; Siguret V; Drouet L; Dillinger JG
    Arch Cardiovasc Dis; 2021 Oct; 114(10):612-623. PubMed ID: 34275780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High and low on-treatment platelet reactivity to P2Y
    Ferreiro JL; Vivas D; De La Hera JM; Marcano AL; Lugo LM; Gómez-Polo JC; Silva I; Tello-Montoliu A; Marín F; Roldán I
    Thromb Res; 2019 Mar; 175():95-101. PubMed ID: 30738371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
    Deharo P; Quilici J; Camoin-Jau L; Johnson TW; Bassez C; Bonnet G; Fernandez M; Ibrahim M; Suchon P; Verdier V; Fourcade L; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2560-2570. PubMed ID: 29268886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients.
    Li DD; Wang XY; Xi SZ; Liu J; Qin LA; Jing J; Yin T; Chen YD
    J Geriatr Cardiol; 2016 May; 13(4):282-9. PubMed ID: 27403136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis.
    Zhang H; Zhang P; Dong P; Yang X; Wang Y; Zhang H; Yan J; Zhang Y; Zhang T; Li Y
    Coron Artery Dis; 2017 Nov; 28(7):597-604. PubMed ID: 28968313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
    Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Prasugrel and Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
    Fong LCW; Lee NHC; Yan AT; Ng MY
    Cardiology; 2022; 147(1):1-13. PubMed ID: 34743081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity.
    Bonello L; Laine M; Baumstarck K; Fernandez J; Maillard L; Peyrol M; Bessereau J; Aradi D; Camilleri E; Roubille F; Piot C; Paganelli F; Camoin-Jau L; Dignat-George F
    Int J Cardiol; 2013 Oct; 168(4):4244-8. PubMed ID: 23911273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events.
    Alexopoulos D; Stavrou K; Koniari I; Gkizas V; Perperis A; Kontoprias K; Vogiatzi C; Bampouri T; Xanthopoulou I
    Thromb Haemost; 2014 Sep; 112(3):551-7. PubMed ID: 24990396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
    Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.